Advances in Survival of Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: closed (1 June 2024) | Viewed by 3390
Special Issue Editors
2. Department of Health Care Science, Faculty of Humanities, T. Bata University in Zlin, Zlin, Czech Republic
Interests: glioblastoma
Special Issue Information
Dear Colleagues,
Glioblastoma (GBM) is the most common malignant brain tumor in adults and has a poor prognosis with near-inevitable recurrence. Many medical teams around the world strive for the substantial prolongation of GBM patients’ life expectancy and improving their quality of life.
Aggressive multimodal therapy that involves maximally radical and safe tumor resection followed by the Stupp oncotherapy protocol has yielded the best treatment outcomes. Preoperative and intraoperative imaging tools and techniques such as MRI, Raman spectroscopy, fluorescence-guided surgery, awake surgery and intraoperative brain mapping have made it possible to maximize tumor cytoreduction and minimize surgical morbidity during neurosurgery, improving GBM patients’ life expectancy. This can also be followed by oncotherapy, including different radiotherapeutic (stereotactic radiotherapy, intensity-modulated radiotherapy, image-guided radiotherapy, hypofractionated schedules, etc.), tumor-treating-field (TTF) techniques, label or off-label systemic therapy (immune checkpoint inhibitors, PARP inhibitor, adaptive T-cell therapy, topoisomerase inhibitor, autologous dendritic cells, FASN inhibitor, PI3K/mTOR inhibitor, VEGFR2-TIE2 tyrosine kinase inhibitor, JAK1/3 inhibitor, oncolytic viruses, peptide vaccines, etc.), in the attempt to change GBM patients’ destiny.
The rate of increase in patient survival at the beginning of the temozolomid era was gradually slow and has plateaued in the last 5–10 years.
This Special Issue will present and share ideas, philosophy and experiences about GBM treatment, focused on advanced treatment strategies.
Dr. Ondrej Kalita
Dr. Tomas Kazda
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- oncotherapy
- life expectancy
- overall survival
- quality of life